Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference
April 22 2022 - 7:30AM
Business Wire
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage
regenerative medicine company focused on developing therapeutics to
activate a person’s innate regenerative potential to restore
function, today announced that Chief Scientific Officer Dr.
Christopher Loose and Vice President of Discovery Biology Dr.
Sanjay Magavi will participate in a fireside presentation at the B.
Riley Securities’ Neuro & Ophthalmology Conference on April 28,
2022 at 3:30 pm ET.
A live webcast of both the panel and presentation can be
accessed on the Investors & Media section of Frequency’s
website and a replay will be posted following the event.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative
medicine that aims to restore human function – first in hearing
loss and then in multiple sclerosis (MS) – by developing
therapeutics that activate a person’s innate regenerative potential
within the body through the activation of progenitor cells.
Frequency’s hearing research focuses on cochlear restoration and
auditory repair, and its lead asset, FX-322, is a small-molecule
product candidate that is the first to show statistically
significant and clinically meaningful hearing improvements in
clinical trials for sensorineural hearing loss. Frequency is also
following early restorative signals in MS to develop medicines with
the same underlying regenerative science being brought to hearing
loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S.
license and collaboration agreement with Astellas Pharma Inc. for
FX-322, as well as additional collaboration and licensing
agreements with academic and nonprofit research organizations
including Massachusetts Eye and Ear, Mass General Brigham, the
Massachusetts Institute of Technology, the Scripps Research
Institute and Cambridge Enterprises Limited.
For more information, visit www.frequencytx.com and follow
Frequency on Twitter @Frequencytx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220422005075/en/
Investor Contact: Carlo Tanzi, Ph.D. Kendall Investor Relations
ctanzi@kendallir.com 617-914-0008
Media Contact: Suzanne Day Frequency Therapeutics Tel:
781-496-2211 Email: sday@frequencytx.com
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Apr 2023 to Apr 2024